ISPOR’s Top 10 HEOR Trends for 2024-2025

By HEOR Staff Writer

January 12, 2024

Introduction:

The International Society for Health Economics and Outcomes Research (ISPOR) recently released its biennial report detailing the top 10 Health Economics and Outcomes Research (HEOR) trends for 2024-2025. This report, the fifth of its kind, offers a compelling glimpse into the future of healthcare. Providing key trends such as Real-World Evidence (RWE), drug pricing, and Artificial Intelligence (AI) taking centre stage.

The Dominance of Real-World Evidence:

RWE has consistently featured in ISPOR’s reports, therefore appearing as the top trend in the three most recent publications. It is increasingly being used to supplement Randomised Controlled Trials (RCTs) in healthcare decision-making, highlighting its growing significance in the industry.

The Recurring Theme of Drug Pricing:

Drug pricing remains a critical concern, featuring as the second trend in the report. However, the introduction of the Inflation Reduction Act (IRA) in the United States, which allows Medicare to negotiate drug prices, could potentially impact global drug development and innovation.

The Rise of Artificial Intelligence:

AI, the third trend, is becoming an integral part of our daily lives and the healthcare sector. From chatbots to machine learning, AI is being utilised in various ways to provide valuable insights in HEOR.

Balancing Innovation and Affordability:

Furthermore, the fourth trend focuses on fostering innovation while ensuring affordable pricing. This balance is vital for the development of new technologies in the healthcare sector.

In conclusion, the ISPOR HEOR trends report presents a comprehensive overview of the top trends shaping the future of healthcare. As pressures on healthcare systems worldwide continue to increase, these trends provide invaluable insights for stakeholders to inform and improve healthcare decisions.

Reference url

Recent Posts

Conditional Reimbursement in Chronic Pain Rehabilitation: Navigating Evidence Gaps and Patient Ac...

By João L. Carapinha

April 20, 2026

Healthcare stakeholders were informed in the Netherlands that Chronic Pain Rehabilitation through Interdisciplinary Medical Specialist Rehabilitation (IMSR) will be removed from the Dutch basic health insurance package for most patients. Under the new ruling by Zorginstituut Nederland, chronic pa...
Advancing Psychedelic Therapy Access for Treatment-Resistant Mental Illness
An Executive Order signed by President Donald J. Trump on April 18, 2026, will significantly advance psychedelic therapy access for serious mental illness. By removing regulatory and scheduling barriers, the order directs the FDA to issue Commissioner’s National Priority Vouchers for eligible psy...
Null Link Confirmed: Prenatal Acetaminophen Autism Risk Study in Denmark

By HEOR Staff Writer

April 17, 2026

A major nationwide Danish cohort study has found no link between maternal acetaminophen use during pregnancy and autism in children. The new evidence on prenatal acetaminophen autism risk should reassure clinicians and expectant mothers, as both population-wide and sibling-controlled analyses sho...